Adaptimmune Therapeutics plc ADAPY · Stock Open Adaptimmune Therapeutics plc in new tab

0.0250 USD

Add to portfolio

EPS

-0.67

P/B

0.26

ROE

-346.65

Beta

0.75

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF valuation

Model fair value for Adaptimmune Therapeutics plc (ADAPY)

Result

Sign in to run the valuation for ADAPY.

Model fair value

–

Price

–

Model vs price

–

WACC – Terminal value PV – Σ PV of cash flows –

Fair value per share by discount rate (rows) and terminal growth (columns)
WACC \ g

Assumptions

Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Adaptimmune Therapeutics plc Analysis (ADAPY)

USA Official Website Stock

Is Adaptimmune Therapeutics plc a good investment? Adaptimmune Therapeutics plc (ADAPY) is currently trading at 0.0250 USD.

Earnings Schedule: Adaptimmune Therapeutics plc is expected to release its next earnings report on Nov. 12, 2026.

Investor FAQ

Does Adaptimmune Therapeutics plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adaptimmune Therapeutics plc?

Adaptimmune Therapeutics plc is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.67.

Company Profile

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Trades

No dividend information available for this instrument.

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.